Primary endoscopic therapies for obesity and metabolic diseases

Current Opinion in Gastroenterology

Volumn 31, Issue 5, 2015, Pages 351-358

  Kumbhari, Vivek ^a,c   Oberbach, Andreas ^b   Nimgaonkar, Ashish ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF LEIPZIG HEART CENTER   (Germany)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Bariatric endoscopy; Duodenal jejunal bypass sleeve; Endoscopic plication; Gastric pouch reduction; Gastrojejunal anastomosis reduction; Intragastric balloon; Obesity; Transoral gastroplasty

Indexed keywords

BOTULINUM TOXIN A;

ABLATION THERAPY; ARTICULATING CIRCULAR STAPLER; ASPIRATION; BARIATRIC SURGERY; CLINICAL ASSESSMENT; DIGESTIVE ENDOSCOPE; DUODENO JEJUNAL BYPASS SLEEVE; ENDOSCOPIC SLEEVE GASTROPLASTY; ENDOSCOPIC THERAPY; ENDOSCOPIST; EVALUATION STUDY; GASTRIC BALLOON; GASTRO DUODENO JEJUNAL BYPASS SLEEVE; GASTROINTESTINAL SURGERY; GASTROPLASTY; HUMAN; INTERVENTION STUDY; METABOLIC DISORDER; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; REVITA DUODENAL MUCOSAL RESURFACING; STAPLER; TRANSPYLORIC SHUTTLE; WEIGHT REDUCTION; ADULT; ALGORITHM; COMPLICATION; COST BENEFIT ANALYSIS; ENDOSCOPY; EPIDEMIOLOGY; METABOLIC DISEASES; UNITED STATES;

ADULT; ALGORITHMS; BARIATRIC SURGERY; COST-BENEFIT ANALYSIS; ENDOSCOPY; HUMANS; METABOLIC DISEASES; OBESITY; UNITED STATES; WEIGHT LOSS;

EID: 84942516455     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000203     Document Type: Review

References (51)

1. American College of Cardiology/American Heart Association Task Force on Practice Guidelines OEP. Executive summary: guidelines (2013) for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society published by the Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Based on a systematic review from the The Obesity Expert Panel, 2013. Obesity 2014; 22 (Suppl 2):S5-S39.
2. Stevens J, Oakkar EE, Cui Z, et al. US adults recommended for weight reduction by 1998 and 2013 obesity guidelines, NHANES 2007-2012. Obesity 2015; 23:527-531.
3. Hampp C, Kang EM, Borders-Hemphill V. Use of prescription antiobesity drugs in the United States. Pharmacotherapy 2013; 33:1299-1307.
4. American Society for Metabolic and Bariatric Surgery. Estimate of bariatric surgery numbers. 2014. Available at http://asmbs.org/2014/03/estimate-ofbariatric- surgery-numbers/. [Accessed 5 April 2015]
5. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357:741-752.
6. AfHRaQ. Statistical Brief #23. Bariatric surgery utilization and outcomes in 1998 and 2004 2007 [cited 2014 October 23]. Available from: http://www.hcup- us.ahrq.gov/reports/statbriefs/sb23.jsp.
7. Flum DR, Belle SH, King WC, et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009; 361:445-454.
8. Lopez-Nava G, Galvao MP, da Bautista-Castano I, et al. Endoscopic sleeve gastroplasty for the treatment of obesity. Endoscopy 2015; 47:449-452. doi: 10.1055/s-0034-1390766.
9. Keith JN. Endoscopic management of common bariatric surgical complications. Gastrointest Endosc Clin N Am 2011; 21:275-285.
10. Pories WJ. Bariatric surgery: risks and rewards. J Clin Endocrinol Metab 2008; 93 (11 Suppl 1):S89-S96.
11. Parikh MS, Laker S, Weiner M, et al. Objective comparison of complications resulting from laparoscopic bariatric procedures. J Am Coll Surg 2006; 202:252-261.
12. Acosta A, Abu Dayyeh BK, Port JD, Camilleri M. Recent advances in clinical practice challenges and opportunities in the management of obesity. Gut 2014; 63:687-695.
13. Ginsberg GG, Chand B, Cote GA, et al., Therapy AATFoEB. A pathway to endoscopic bariatric therapies. Gastrointest Endosc 2011; 74:943-953.
14. Ikramuddin S, Blackstone RP, Brancatisano A, et al. Effect of reversible intermittent intra-abdominal vagal nerve blockade on morbid obesity: the ReCharge randomized clinical trial. JAMA 2014; 312:915-922.
15. Tsigos C, Hainer V, Basdevant A, et al. Criteria for EASO-collaborating centres for obesity management. Obes Facts 2011; 4:329-333.
16. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009; 360:859-873.
17. Dietz WH, Baur LA, Hall K, et al. Management of obesity: improvement of health-care training and systems for prevention and care. Lancet 2015.
18. Pasricha PJ. Hunger games: is your stomach making you fat? Gastroenterology 2015; 148:491-493.
19. Kotzampassi K, Grosomanidis V, Papakostas P, et al. 500 intragastric balloons: what happens 5 years thereafter? Obes Surg 2012; 22:896-903.
20. Genco A, Dellepiane D, Baglio G, et al. Adjustable intragastric balloon vs nonadjustable intragastric balloon: case-control study on complications, tolerance, and efficacy. Obes Surg 2013; 23:953-958.
21. Tai CM, Lin HY, Yen YC, et al. Effectiveness of intragastric balloon treatment for obese patients: one-year follow-up after balloon removal. Obes Surg 2013; 23:2068-2074.
22. Fuller NR, Pearson S, Lau NS, et al. An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study. Obesity 2013; 21:1561-1570.
23. Al Kahtani K, Khan MQ, Helmy A, et al. Bio-enteric intragastric balloon in obese patients: a retrospective analysis of King Faisal Specialist Hospital experience. Obes Surg 2010; 20:1219-1226.
24. Takihata M, Nakamura A, Aoki K, et al. Comparison of intragastric balloon therapy and intensive lifestyle modification therapy with respect to weight reduction and abdominal fat distribution in super-obese Japanese patients. Obes Res Clin Pract 2014; 8:e331-e338.
25. Genco A, Cipriano M, Bacci V, et al. BioEnterics Intragastric Balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes 2006; 30:129-133.
26. Farina MG, Baratta R, Nigro A, et al. Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. Obes Surg 2012; 22:565-571.
27. Ponce J, Quebbemann BB, Patterson EJ. Prospective, randomized, multicenter study evaluating safety and efficacy of intragastric dual-balloon in obesity. Surg Obes Related Dis 2013; 9:290-295.
28. Mui WL, Ng EK, Tsung BY, et al. Impact on obesity-related illnesses and quality of life following intragastric balloon. Obes Surg 2010; 20:1128-1132.
29. Busetto L, Enzi G, Inelmen EM, et al. Obstructive sleep apnea syndrome in morbid obesity: effects of intragastric balloon. Chest 2005; 128:618-623.
30. Lee YM, Low HC, Lim LG, et al. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. Gastrointestinal Endosc 2012; 76:756-760.
31. Marinos G, Eliades C, Raman Muthusamy V, Greenway F. Weight loss and improved quality of life with a nonsurgical endoscopic treatment for obesity: clinical results from a 3- and 6-month study. Surg Obes Related Dis 2014; 10:929-934.
32. Abu Dayyeh BK, Rajan E, Gostout CJ. Endoscopic sleeve gastroplasty: a potential endoscopic alternative to surgical sleeve gastrectomy for treatment of obesity. Gastrointestinal Endosc 2013; 78:530-535.
33. Sharaiha RZ, Kedia P, Kumta N, et al. Initial experience with endoscopic sleeve gastroplasty: technical success and reproducibility in the bariatric population. Endoscopy 2015; 47:164-166.
34. Lopez-Nava Breviere G, Bautista-Castano I, Jimenez A, et al. The Primary Obesity Surgery Endolumenal (POSE) procedure: one-year patient weight loss and safety outcomes. Surg Obes Relat Dis 2014. [Epub ahead of print]
35. Verlaan T, Paulus GF, Mathus-Vliegen EM, et al. Endoscopic gastric volume reduction with a novel articulating plication device is safe and effective in the treatment of obesity (with video). Gastrointest Endosc 2015; 81:312-320.
36. Forssell H, Noren E. A novel endoscopic weight loss therapy using gastric aspiration: results after 6 months. Endoscopy 2015; 47:68-71.
37. Sullivan S, Stein R, Jonnalagadda S, et al. Aspiration therapy leads to weight loss in obese subjects: a pilot study. Gastroenterology 2013; 145:1245-1252.
38. Devault KR. Could aspiration therapy for obesity be an effective and safe alternative to traditional bariatric surgery? Gastroenterology 2013; 145:1188-1190.
39. Bang CS, Baik GH, Shin IS, et al. Effect of intragastric injection of botulinum toxin A for the treatment of obesity: a meta-analysis and meta-regression. Gastrointest Endosc 2015; 81:1141-1149.
40. Escalona A, Pimentel F, Sharp A, et al. Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner. Ann Surg 2012; 255:1080-1085.
41. de Moura EG, Martins BC, Lopes GS, et al. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. Diab Technol Ther 2012; 14:183-189.
42. Koehestanie P, de Jonge C, Berends FJ, et al. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg 2014; 260:984-992.
43. Schouten R, Rijs CS, Bouvy ND, et al. A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Ann Surg 2010; 251:236-243.
44. Rodriguez L, Reyes E, Fagalde P, et al. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Ther 2009; 11:725-732.
45. de Jonge C, Rensen SS, Koek GH, et al. Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013; 11:1517-1520.
46. Zechmeister-Koss I, Huic M, Fischer S; European Network for Health Technology A. The duodenal-jejunal bypass liner for the treatment of type 2 diabetes mellitus and/or obesity: a systematic review. Obes Surg 2014; 24:310-323.
47. Sandler BJ, Rumbaut R, Swain CP, et al. One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity. Surg Endosc 2015. [Epub ahead of print]
48. Acosta A, Camilleri M, Shin A, et al. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy. Gastroenterology 2015; 148:537-546.
49. Talebpour A, Heidari R, Zeinoddini A, Talebpour M. Predictors of weight loss after laparoscopic gastric plication: a prospective study. J Laparoendoscopic Adv Surg Tech Part A 2015; 25:177-181.
50. Chikunguwo SM, Wolfe LG, Dodson P, et al. Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2010; 6:254-259.
51. Martini F, Anty R, Schneck AS, et al. Predictors of metabolic syndrome persistence 1 year after laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis 2015. [Epub ahead of print]